Marcelino Gonzalez-Padilla1, Julián Torre-Cisneros2, Francisco Rivera-Espinar3, Antonio Pontes-Moreno3, Lorena López-Cerero4, Alvaro Pascual4, Clara Natera1, Marina Rodríguez3, Inmaculada Salcedo5, Fernando Rodríguez-López6, Antonio Rivero1, Jesús Rodríguez-Baño4. 1. Clinic Unit of Infectious Diseases, Hospital Universitario Reina Sofía-IMIBIC-Universidad de Córdoba, Córdoba, Spain. 2. Clinic Unit of Infectious Diseases, Hospital Universitario Reina Sofía-IMIBIC-Universidad de Córdoba, Córdoba, Spain Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain julian.torre.sspa@juntadeandalucia.es. 3. Intensive Care Unit, Hospital Universitario Reina Sofía, Córdoba, Spain. 4. Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Seville, Spain Departamento de Medicina, Universidad de Sevilla, Seville, Spain. 5. Clinic Unit of Preventive Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain. 6. Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain Clinic Unit of Microbiology, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Abstract
OBJECTIVES: Antimicrobial therapy for sepsis caused by carbapenem- and colistin-resistant Klebsiella pneumoniae is not well established. We hypothesized that the early use of gentamicin in cases due to susceptible organisms would decrease the crude mortality rate of this infection. METHODS: This retrospective cohort study examined 50 cases of sepsis caused by carbapenem-resistant K. pneumoniae occurring between June 2012 and February 2013 during an outbreak of K. pneumoniae ST512 producing KPC-3, SHV-11 and TEM-1. Survival curves categorized by the use of gentamicin were constructed using the Kaplan-Meier method and compared using the log-rank test. Eight multivariate models using Cox regression were designed to study the risk factors for mortality and test the hypothesis. RESULTS: The 30 day crude mortality rate was 38%. The use of targeted gentamicin was associated with reduced mortality (20.7% versus 61.9%, P = 0.02). In all multivariate regression models, the use of gentamicin was independently associated with lower mortality until Day 30 (HR 0.17-0.29, P = 0.03-0.002 depending on the model) after controlling for other potential confounding variables such as age, optimal treatment, renal function, severity of infection, underlying disease, use of tigecycline and previous hospitalization. CONCLUSIONS: Gentamicin reduced the mortality from sepsis caused by this K. pneumoniae ST512 clone producing KPC-3, SHV-11 and TEM-1.
OBJECTIVES: Antimicrobial therapy for sepsis caused by carbapenem- and colistin-resistant Klebsiella pneumoniae is not well established. We hypothesized that the early use of gentamicin in cases due to susceptible organisms would decrease the crude mortality rate of this infection. METHODS: This retrospective cohort study examined 50 cases of sepsis caused by carbapenem-resistant K. pneumoniae occurring between June 2012 and February 2013 during an outbreak of K. pneumoniae ST512 producing KPC-3, SHV-11 and TEM-1. Survival curves categorized by the use of gentamicin were constructed using the Kaplan-Meier method and compared using the log-rank test. Eight multivariate models using Cox regression were designed to study the risk factors for mortality and test the hypothesis. RESULTS: The 30 day crude mortality rate was 38%. The use of targeted gentamicin was associated with reduced mortality (20.7% versus 61.9%, P = 0.02). In all multivariate regression models, the use of gentamicin was independently associated with lower mortality until Day 30 (HR 0.17-0.29, P = 0.03-0.002 depending on the model) after controlling for other potential confounding variables such as age, optimal treatment, renal function, severity of infection, underlying disease, use of tigecycline and previous hospitalization. CONCLUSIONS:Gentamicin reduced the mortality from sepsis caused by this K. pneumoniae ST512 clone producing KPC-3, SHV-11 and TEM-1.
Authors: Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Francisco Rivera-Espinar; Isabel Machuca; Rocio Tejero; Jorge Rodríguez; Ana Mula; Eduardo Marfil; Ángela Cano; Belén Gutiérrez-Gutiérrez; Marina Rodríguez; Juan Carlos Pozo; Carmen De la Fuente; Jesús Rodriguez-Baño; Luis Martínez-Martínez; Rafael León; Julian Torre-Cisneros Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191
Authors: F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi Journal: Acta Otorhinolaryngol Ital Date: 2018-04 Impact factor: 2.124